The addition of pemafibrate to UDCA therapy in PBC patients with dyslipidemia led to significant medium-term improvements in ALP, GGT, and ALT levels, with a sustained increase in the ALP normalization rate during four years of treatment. The gene discussed is GPT; the disease is metabolic syndrome.